Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) EBIT Margin (2021 - 2024)

Allogene Therapeutics (ALLO) has disclosed EBIT Margin for 4 consecutive years, with 315927.27% as the latest value for Q1 2024.

  • Quarterly EBIT Margin rose 1437939.0% to 315927.27% in Q1 2024 from the year-ago period, while the trailing twelve-month figure was 1241813.64% through Dec 2024, down 89682732.0% year-over-year, with the annual reading at 1241813.64% for FY2024, 89682732.0% down from the prior year.
  • EBIT Margin hit 315927.27% in Q1 2024 for Allogene Therapeutics, up from 405280.95% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 2.26% in Q4 2021 to a low of 405280.95% in Q4 2023.
  • Historically, EBIT Margin has averaged 232707.56% across 4 years, with a median of 286345.45% in 2023.
  • Biggest YoY gain for EBIT Margin was 4171705bps in 2022; the steepest drop was -37075226bps in 2022.
  • Year by year, EBIT Margin stood at 2.26% in 2021, then plummeted by -16431036bps to 370750.0% in 2022, then dropped by -9bps to 405280.95% in 2023, then increased by 22bps to 315927.27% in 2024.
  • Business Quant data shows EBIT Margin for ALLO at 315927.27% in Q1 2024, 405280.95% in Q4 2023, and 286345.45% in Q3 2023.